Emily earned her B.S. in biopsychology in 2020 from the University of California, Santa Barbara. Prior to joining MAPS Public Benefit Corporation (MPBC), Emily was involved with UCSB’s chapter of Students for Sensible Drug Policy, participated in the SSDP Psychedelic Pipeline program, and founded a chapter of Psychedelic Club on campus. Emily also spent time working as an intern at Massachusetts General Hospital in the Center for Addiction Medicine, where she helped with a study investigating the effects of medical marijuana on neurocognition.

At MPBC, Emily is currently serving as a Clinical Research Associate (CRA) working on Phase 3 MDMA-Assisted psychotherapy studies for patients with posttraumatic stress disorder (PTSD). Emily is passionate about drug policy reform and harm reduction strategies. She is excited to support the Clinical Operations team and believes psychedelic medicine plays an important role in developing a more holistic model of mental healthcare. In her free time, Emily enjoys skiing, cooking, and camping.